NCT06447623 2024-06-07
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Fudan University
Phase 3 Recruiting
Clinical Trials
4 trialsNCT03927456 2021-06-03
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT00327769 2011-01-25
Faslodex Advanced Breast Cancer Local Chinese Study
AstraZeneca
Phase 3 Completed
NCT00635713 2009-04-10
Second Line Breast Cancer Trial
AstraZeneca
Phase 3 Completed